Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Maintenance After Allo-SCT for AML/MDS
NCT02485535Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Sep 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 29 days. Started Sep 2015; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02485535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485535.